Hexagon Nutrition — Q2 and H1 FY27 — 17 November 2026
1. Overall Tone of Management
Cautious. Management expressed confidence in growth and H2 demand, but the quarter’s underlying picture is mixed: Q2 revenue growth slowed to 15% year on year from Q1’s 43%, gross margin remained well below the prior-year level, and inventory rose sharply. Management described margin recovery as an opportunity and said actions were “already working,” but most of the recovery is still expected over the next few quarters.
2. Key Themes from Management Commentary
- Growth remains healthy but uneven: H1 revenue rose 27.3% year on year. Q2 revenue grew 15.2% year on year and 5.1% sequentially. Management attributed H1 growth to higher sales volume and value in branded and premix businesses.
- Margin recovery is the central operating priority: Q2 gross margin improved to 47% from 43.9% in Q1, but was down from 53.1% a year earlier. Management cited higher whey and other raw-material costs, alongside product mix, and pointed to pricing, procurement and mix initiatives.
- Working capital is absorbing cash: Inventory increased from ₹84 crore in March to ₹136 crore in September. Management said the build reflects secured raw materials and orders awaiting customer letters of credit. H1 operating cash flow was negative ₹8.6 crore, mainly due to inventory.
- ESG revenue is lumpy and execution-dependent: Management disclosed an ESG order book of about ₹100 crore, with roughly ₹75 crore expected to ship in H2. Some Q2 ESG dispatches were held up while the company awaited letters of credit.
- Branded growth requires continued investment: Employee costs rose as the company expanded its field force and invested in R&D, quality, sales and compliance. Pentasure accounts for more than 95% of branded sales; Pedia Gold and Obesigo are still growing.
- Expansion without major near-term capacity additions: Blended utilization was described as about 30%, with plant utilization varying. Management said existing facilities could support another ₹200–300 crore of revenue before major capacity investment, apart from the Nashik reconstruction.
- New products and markets: A stable powdered Vitamin A product is being developed for fortification/ESG use. Management is also targeting Europe and North America for premix growth and expects more Uzbekistan orders by Q4.
3. Q&A Analysis
Margins, raw materials and profitability
- Analysts asked: Why PAT did not keep pace with revenue; which inputs drove gross-margin pressure; whether raw-material prices were stabilizing; and when margins might recover.
- Management responded: Higher raw-material costs—particularly whey and other premix inputs—were the main pressure, alongside increased employee and administrative costs and a one-time plant-disposal loss. Input prices were “fairly stable” in Q2. Pricing increases, supplier diversification, longer contracts and a higher-margin mix are expected to improve margins.
- Assessment: Management was confident that margins would improve, but gave no quantified margin target. The gap between 47% Q2 gross margin and 53.1% a year earlier remains material. The stated price benefit is still prospective.
- Quote: “The biggest opportunity in front of us is the margin.”
Growth outlook, order book and ESG dispatches
- Analysts asked: Whether H1 growth would continue in H2, how seasonality affects results, and how much of the order book would be executed.
- Management responded: It maintained FY27 revenue-growth guidance of 20%–25%. The ESG order book is about ₹100 crore, with approximately ₹75 crore expected to ship in H2; premix orders are ongoing. Management attributed weaker Q2 total growth partly to ESG orders awaiting letters of credit.
- Assessment: The outlook is supported by orders, but execution depends on customer documentation and the timing of lumpy ESG shipments. Management did not raise guidance despite H1 growth exceeding the full-year target pace.
Inventory, cash flow and working capital
- Analysts asked: Why inventory rose and whether it would affect H2 profitability and cash generation.
- Management responded: Inventory was built for confirmed orders, to secure raw materials ahead of expected price increases, and while awaiting customer letters of credit. It said inventory should normalize as orders ship—potentially in Q3, and in the prepared remarks by March 2027.
- Assessment: The timing is not fully consistent: Q&A suggested normalization in Q3, while prepared remarks said by March 2027. The inventory build is substantial relative to the negative H1 operating cash flow.
- Quote: “The inventory we have built secures our supply for the second half and will convert to cash.”
Capacity, capex and Nashik reconstruction
- Analysts asked: Plant utilization, available revenue headroom and H2/FY28 capex.
- Management responded: Blended utilization was around 30%; Nashik was above 55%, Chennai about 25% and Tuticorin around 26%. Management said existing capacity could support another ₹200–300 crore of revenue. The Nashik reconstruction is the principal capex, with around ₹2–3 crore of routine repairs otherwise.
- Assessment: Capacity figures are difficult to compare with Q1, when blended utilization was repeatedly described as 40%–47%. Management did not explain the difference in definitions or measurement.
Customer and geographic diversification; competitive position
- Analysts asked: About concentration, export mix, market position and competitiveness.
- Management responded: Around 50%–55% or more of Q2 sales were domestic, with the balance from exports. Around 30%–40% of sales came from a few premix customers. Management said it intends to diversify through branded growth and new premix markets in Europe and North America. It described Hexagon as third in India’s clinical nutrition market and a major domestic premix supplier.
- Assessment: Management supplied useful concentration estimates but gave limited detail on a timeline or measurable diversification goals.
Product development and newer geographies
- Analysts asked: About the Vitamin A opportunity and Uzbekistan’s role.
- Management responded: The stable powdered Vitamin A product is intended for food fortification within ESG; commercialization is being worked out, with market-size details deferred to the next quarter. Uzbekistan is undergoing customer audits and management expects more orders by Q4.
- Assessment: Both opportunities remain early-stage, with no quantified revenue contribution yet.
4. Guidance / Outlook
Quantitative guidance
- FY27 revenue growth: Maintain 20%–25% year on year; management also said it believes a similar rate is achievable over the next couple of years.
- ESG order book: Approximately ₹100 crore, of which about ₹75 crore is expected to ship in H2.
- Inventory: Expected to normalize by March 2027 in prepared remarks; Q&A also suggested it could normalize in Q3.
- Capex: Nashik reconstruction is the main project; total project estimates across the call range around ₹25 crore to ₹25–30 crore, with approximately ₹20 crore of bank financing. Routine repair capex of ₹2–3 crore may also be incurred.
- Capacity headroom: Management said existing facilities could accommodate another ₹200–300 crore of revenue before requiring additional capacity.
Qualitative signals
- Revenue momentum is expected to continue in H2, supported by branded field-force expansion and premix/ESG orders.
- Gross margins are expected to improve progressively as pricing, procurement and product-mix actions take effect; no numerical margin target was provided.
- Management expects employee costs to stabilize around Q2 levels.
- Uzbekistan orders may increase by Q4; commercialization plans for the new Vitamin A product are still being worked out.
- Nashik reconstruction is underway; no other major capex was indicated.
5. Standout Statements
- “The biggest opportunity in front of us is the margin.”
- “We will maintain our guidance of 20% to 25% year-on-year growth.”
- “The inventory we have built secures our supply for the second half and will convert to cash.”
- “We are currently in third position” in the Indian clinical nutrition market, according to management.
- Management said Pentasure contributes more than 95% of branded sales, highlighting the concentration within the branded portfolio.
- Management is considering whether to continue or wind up its South African trading entity, which had no business this year.
- Management’s claim that the Vitamin A powder is a “major breakthrough globally” is notable, but commercialization and the opportunity size remain unquantified.
6. Red Flags / Positive Signals
Red flags
– Gross margin remains 610 basis points below Q2 FY26 despite sequential improvement.
– Inventory rose by ₹52 crore in six months and was a primary driver of negative operating cash flow.
– Inventory normalization timing differs between prepared remarks and Q&A.
– Capacity utilization was reported as 47% in Q1 but about 30% in the current call, without a clear reconciliation.
– The transcript gives inconsistent H1 PAT comparisons: the opening remarks compare ₹16.2 crore with ₹16.6 crore, while the financial review compares it with ₹15.6 crore. This should be checked against filings.
– Pentasure represents over 95% of branded sales; the portfolio remains concentrated.
– New-product and new-market opportunities are not yet quantified.
Positive signals
– H1 revenue grew 27.3%, with strong branded and premix contributions.
– Gross margin improved about 310 basis points sequentially.
– Management reports secured raw-material supplies and an ESG order book supporting H2 shipments.
– The company remained net cash positive, with ₹46.5 crore in cash, deposits and liquid funds against ₹37.4 crore of borrowings.
– Receivables declined from ₹82 crore to ₹77 crore.
7. Historical Comparison & Consistency Analysis
a. Quarter-by-Quarter Tone Evolution
Period unavailable — third-last transcript not provided
- Dominant tone: Not assessable
- Major themes this quarter: Transcript unavailable.
- Tone shift vs previous quarter: N/A (baseline)
- What changed: Cannot determine from the material provided.
Q4 FY26 — quarter and year ended 31 March 2026; call held 17 July 2026
- Dominant tone: Optimistic
- Major themes this quarter:
- FY26 revenue grew 17.8%, EBITDA 32.0% and PAT 56.1%.
- Branded nutrition was emphasized as a growth and margin driver.
- Management highlighted Tier-2/3 expansion, e-commerce and sales-force investment.
- It expected operating leverage and margins to improve with growth.
- Tone shift vs previous quarter: N/A (baseline among available transcripts)
- What changed: First earnings call as a listed company; management set a confident narrative around profitable growth, diversification and capacity headroom.
Q1 FY27 — quarter ended 30 June 2026; call held 14 August 2026
- Dominant tone: Optimistic
- Major themes this quarter:
- Revenue grew 43.2% year on year, while EBITDA grew more slowly and margin fell to 11.3%.
- Raw-material inflation and freight costs—linked by management to West Asia—were pressuring margins.
- Management cited 10%–15% branded-product MRP increases and expected relief in coming quarters.
- Field-force expansion, branded growth and Nashik reconstruction were emphasized.
- Tone shift vs previous quarter: No Change
- What changed:
- The confident FY26 growth narrative gained a specific near-term risk: input-cost and freight inflation.
- Management expected pricing benefits from Q2 onward and said new sales-force productivity should emerge around Q3.
- FY27 growth guidance was set at 20%–25%.
Q2 / H1 FY27 — quarter and half year ended 30 September 2026; call held 17 November 2026
- Dominant tone: Cautiously optimistic
- Major themes this quarter:
- H1 revenue rose 27.3%, but Q2 year-on-year growth slowed to 15.2%.
- Gross margin recovered sequentially but remained well below the prior-year quarter.
- Inventory build, delayed ESG dispatches and cash conversion became prominent topics.
- Management maintained 20%–25% growth guidance and highlighted raw-material coverage and H2 orders.
- Tone shift vs previous quarter: More Cautious
- What changed:
- The margin issue moved from a temporary inflation/freight explanation to the company’s “biggest opportunity,” with recovery still expected over coming quarters.
- Working capital became more prominent: inventory rose to ₹136 crore, and H1 operating cash flow turned negative.
- Guidance was maintained despite strong H1 growth, rather than raised.
Trajectory Summary: The narrative moved from strong FY26 performance and broad confidence to Q1 FY27’s explicit cost pressures, then to a more cautious Q2 stance focused on margin repair and inventory conversion. Growth remains solid, but the promised recovery in margins and cash conversion has not yet been fully demonstrated.
b. Tracking Past Commitments vs Outcomes
- Q1 FY27: “20% to 25% growth” for FY27.
- Expected: Full-year growth within that range.
- What happened: H1 revenue grew 27.3%; management maintained, rather than revised, the target.
-
Flag: Pending; not yet possible to assess as delivered.
-
Q1 FY27: 10%–15% MRP increases expected to ease margin pressure from Q2 onward.
- Expected: Pricing benefit beginning in Q2 and continuing over the next quarters.
- What happened: Gross margin rose from 43.9% in Q1 to 47% in Q2, but remained below 53.1% a year earlier; management says further pricing benefit should come over the next one to two quarters.
-
Flag: ⏳ Partial / still unfolding.
-
Q1 FY27: New field-force hires expected to become productive by around Q3.
- Expected: Revenue contribution and operating leverage as the expanded team matures.
- What happened: Q2 management attributed growth partly to the branded business but did not quantify sales-force productivity; employee costs rose.
-
Flag: ⏳ Not yet demonstrated.
-
Q1 FY27: Nashik reconstruction expected to cost ₹25–30 crore over roughly one to one-and-a-half years.
- Expected: Reconstruction work and financing plan to progress.
- What happened: Work has been initiated; current call cites about ₹25 crore and around ₹20 crore of bank funding.
-
Flag: ✅ In progress / broadly consistent.
-
Q1 FY27: Approximately ₹100 crore order book expected to execute mainly in Q2 and partly Q3.
- Expected: Near-term dispatches against the disclosed pipeline.
- What happened: Current call disclosed an ESG order book of about ₹100 crore, with ₹75 crore expected in H2; some Q2 dispatches were delayed pending letters of credit. The scope and timing are not directly comparable.
-
Flag: ⏳ Partial / execution timing shifted.
-
Q4 FY26: Branded share expected to reach 35% “in the next couple of years.”
- Expected: Branded business to rise from roughly 30% of revenue toward 35%.
- What happened: The current call did not update the branded revenue share; it did say Pentasure remains over 95% of branded sales.
- Flag: Not mentioned again; progress cannot be verified from this call.
c. Narrative Shifts
- From broad growth to margin repair: FY26 and Q1 emphasized growth, operating leverage and investment; Q2’s central concern is rebuilding gross margin.
- Working capital moved into the foreground: Inventory was described as manageable/strategic in Q1; Q2’s increase to ₹136 crore and negative operating cash flow made conversion timing a key investor issue.
- ESG execution risk became more specific: The segment’s lumpiness was previously acknowledged; Q2 identified delayed letters of credit as a cause of missed dispatches.
- International growth priorities sharpened: Q1 discussed broad geographic expansion; Q2 specifically highlighted Europe and North America for premix and near-term Uzbekistan approvals/orders.
- Branded growth remains concentrated: Management continues to promote Pedia Gold and Obesigo, but Pentasure’s more-than-95% share of branded revenue shows diversification is still limited.
- Some earlier themes receded: Q1’s West Asia-related freight pressure received less emphasis in Q2, while raw-material costs and mix remained central.
d. Consistency & Credibility Signals
Overall communication credibility: Medium.
Management has been consistent about its 20%–25% growth target, Nashik reconstruction and the need to improve margins. It also disclosed the inventory increase and its working-capital impact. However, margin recovery remains promised rather than established; order-book execution depends on customer documentation; inventory normalization timelines vary; and capacity-utilization figures are not reconciled across calls. The current transcript’s conflicting H1 PAT comparisons further weaken precision.
e. Evolution of Key Themes
- Revenue growth — Stable to improving for H1, but decelerating sequentially: Q1 growth of 43.2% eased to Q2 growth of 15.2%; H1 remained strong at 27.3%.
- Margins — Deteriorating year on year; improving sequentially: Q2 gross margin recovered from Q1 but remained well below Q2 FY26.
- Raw-material costs — Improving/stabilizing, but unresolved: Management said Q2 input prices were fairly stable; full pricing pass-through remains pending.
- Working capital — Deteriorating: Inventory rose sharply and drove negative H1 operating cash flow, despite lower receivables.
- Branded expansion — Stable strategic priority, execution still developing: Field-force and digital investment continue, but Pentasure dominates branded sales.
- ESG / tenders — Stable opportunity, volatile execution: The order book is sizable, but shipment timing is lumpy and dependent on letters of credit and procurement cycles.
- Capacity and capex — Stable: Management continues to claim substantial capacity headroom; Nashik reconstruction is the main investment.
f. Additional Insights (Cross-Period Intelligence)
- The company’s growth guidance has not changed, but the underlying composition of risk has: first raw-material and freight inflation, now delayed ESG dispatches and inventory cash conversion.
- Q1’s expectation that price hikes would relieve margin pressure from Q2 has so far produced only a sequential improvement, not a full year-on-year recovery.
- The large inventory build may protect H2 supply and support orders, but it also makes the credibility of the shipment timetable—especially the ₹75 crore ESG target—important to cash conversion.
- Management’s strong capacity-headroom narrative sits alongside low blended utilization and inconsistent utilization figures, making the precise operational starting point unclear.
